Pluri Inc. (NASDAQ:PLUR)
| Market Cap | $13.51M-74.0% |
| Revenue (ttm) | $2.14M+61.4% |
| Net Income | -$48.47M-115.0% |
| EPS | -$4.55-38.7% |
| Shares Out | 14.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,866 |
| Open | $0.98 |
| Previous Close | $0.97 |
| Day's Range | $0.90 - $1.06 |
| 52-Week Range | $0.85 - $3.94 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | $12.00(+1176.60%) |
| Earnings Date | Mar 3, 2027 |
About PLUR
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Pluri Inc. Stock Analysis — InsiderScore
Pluri Inc. scored higher than 6% of companies evaluated by InsiderBuying, and ranked 89th out of 107 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Pluri Inc. bought $1.25 million of stock across 1 purchase in the last 90 days, the largest of them $1.25 million.
The average purchase added about 67% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 3, 2027Earnings report
$PLUR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PLUR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PLUR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PLUR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PLUR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PLUR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PLUR
| DFISDimensional - International Small Cap ETF | $0.46 |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from PLUR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Certifications, earnings reporting, and CEO commentary on commercial expansion signal positive business momentum and operational progress.
Recent Insider Activity
Insider Score Trend Over Time
-15.3 since Oct 30Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
